BRPI0318049B8 - processo para produção de uma forma farmacêutica oral com imediata desintegração e liberação de ingrediente ativo, pó contendo ingrediente ativo e seu uso - Google Patents

processo para produção de uma forma farmacêutica oral com imediata desintegração e liberação de ingrediente ativo, pó contendo ingrediente ativo e seu uso

Info

Publication number
BRPI0318049B8
BRPI0318049B8 BRPI0318049A BR0318049A BRPI0318049B8 BR PI0318049 B8 BRPI0318049 B8 BR PI0318049B8 BR PI0318049 A BRPI0318049 A BR PI0318049A BR 0318049 A BR0318049 A BR 0318049A BR PI0318049 B8 BRPI0318049 B8 BR PI0318049B8
Authority
BR
Brazil
Prior art keywords
active ingredient
powder containing
active ingredients
producing
dosage form
Prior art date
Application number
BRPI0318049A
Other languages
English (en)
Other versions
BRPI0318049B1 (pt
BR0318049A (pt
Inventor
Gryczke Andreas
Meier Christian
Petereit Hans-Ulrich
Original Assignee
Evonik Roehm Gmbh
Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh, Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of BR0318049A publication Critical patent/BR0318049A/pt
Publication of BRPI0318049B1 publication Critical patent/BRPI0318049B1/pt
Publication of BRPI0318049B8 publication Critical patent/BRPI0318049B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"processo para produção de uma forma farmacêutica oral com imediata desintegração e liberação de ingrediente ativo". a presente invenção refere-se a um processo para produção de uma forma oral de administração que decompõe imediatamente e libera ingredientes ativos na boca. de acordo com o dito processo, (a) um ingrediente ativo farmacêutico aniônico é intensamente misturado com (b) um copolímero consistindo em ésteres c~ 1- 4~ polimerizados com radical, de ácido acrílico ou metacrílico e outros monômeros (met)acrilato contendo grupos amino terciários funcionais, e (c) entre 5 e 50% em peso, em relação a (b), de um ácido carboxílico c~ 12-22~ na massa fundida; a mistura é solidificada e triturada para formar um pó contendo os ingredientes ativos tendo um tamanho de partícula médio de 200 <109>m ou menos; e o pó é encapsulado em uma matriz solúvel em água consistindo em adjuvantes farmaceuticamente padrão, na condição de que não mais que 3% em peso, em relação ao copolímero, de emulsificantes com um valor hlb de pelo menos 14 estejam ali contidos. a invenção também refere-se ao pó contendo ingredientes ativos e os usos do mesmo.
BRPI0318049A 2003-01-28 2003-11-21 processo para produção de uma forma farmacêutica oral com imediata desintegração e liberação de ingrediente ativo, pó contendo ingrediente ativo e seu uso BRPI0318049B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10304403A DE10304403A1 (de) 2003-01-28 2003-01-28 Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
DE10304403.5 2003-01-28
PCT/EP2003/013059 WO2004066976A1 (de) 2003-01-28 2003-11-21 Verfahren zur herstellung einer oralen arzneiform mit unmittelbarem zerfall und wirkstofffreisetzung

Publications (3)

Publication Number Publication Date
BR0318049A BR0318049A (pt) 2005-12-20
BRPI0318049B1 BRPI0318049B1 (pt) 2018-04-03
BRPI0318049B8 true BRPI0318049B8 (pt) 2021-05-25

Family

ID=32667988

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0318049A BRPI0318049B8 (pt) 2003-01-28 2003-11-21 processo para produção de uma forma farmacêutica oral com imediata desintegração e liberação de ingrediente ativo, pó contendo ingrediente ativo e seu uso

Country Status (14)

Country Link
US (2) US8343542B2 (pt)
EP (1) EP1587497B1 (pt)
JP (2) JP5537756B2 (pt)
KR (1) KR100983461B1 (pt)
AU (1) AU2003292061A1 (pt)
BR (1) BRPI0318049B8 (pt)
CA (1) CA2512738C (pt)
DE (1) DE10304403A1 (pt)
ES (1) ES2528359T3 (pt)
IL (1) IL169886A (pt)
MX (1) MXPA05007643A (pt)
PL (1) PL206413B1 (pt)
SI (1) SI1587497T1 (pt)
WO (1) WO2004066976A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US7527807B2 (en) 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
JP5168712B2 (ja) * 2004-04-01 2013-03-27 味の素株式会社 ナテグリニド含有製剤
TW200621240A (en) * 2004-11-05 2006-07-01 Salmedix Inc Cancer treatments
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
FR2882655B1 (fr) * 2005-03-07 2007-04-27 Vetoquinol Sa Sa Nouveau procede d'obtention d'une poudre d'imidapril a dissolution rapide
AU2006242535B2 (en) 2005-04-29 2012-08-09 Merck Sharp & Dohme Corp. Therapeutic compositions
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
CN100336816C (zh) * 2005-12-14 2007-09-12 广州大学 一种舒巴坦制备方法
CN100402030C (zh) * 2006-01-05 2008-07-16 珠海联邦制药股份有限公司 一种含阿莫西林的药物组合物及其制备方法
WO2007090721A1 (de) * 2006-02-03 2007-08-16 Evonik Röhm Gmbh Pharmazeutische zusammensetzungen, enthaltend mischungen aus polymeren und in wasser schlecht löslichen wirkstoffen
DE102007026550A1 (de) 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US8198277B2 (en) * 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8212036B2 (en) * 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8268832B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198278B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CA2735899A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
UA109109C2 (uk) 2009-01-15 2015-07-27 Сефалон, Інк. Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти)
CN102471523A (zh) 2009-07-30 2012-05-23 赢创罗姆有限公司 包含共聚物、二羧酸和脂肪单羧酸的粉末状或粒状组合物
JP5817715B2 (ja) * 2010-03-03 2015-11-18 ライオン株式会社 固形医薬組成物、医薬製剤及び固形医薬組成物の製造方法
EP2568964B1 (en) 2010-05-10 2018-08-01 Evonik Röhm GmbH Pharmaceutical dosage form comprising one or more antiretroviral active ingredients
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
CN102078322B (zh) * 2011-02-17 2013-10-30 武汉同源药业有限公司 注射用哌拉西林钠他唑巴坦钠的医药用途
ES2702848T3 (es) 2011-02-23 2019-03-05 Coeruleus Ltd Complejos de flumazenil, composiciones que los comprenden y usos de los mismos
EP2862569A1 (en) 2011-09-09 2015-04-22 Cubist Pharmaceuticals, Inc. Methods for treating intrapulmonary infections
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
KR102226197B1 (ko) 2013-03-15 2021-03-11 머크 샤프 앤드 돔 코포레이션 세프톨로잔 항균성 조성물
US9320740B2 (en) 2013-03-15 2016-04-26 Merck Sharp & Dohme Corp. Ceftolozane-tazobactam pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
WO2015035376A2 (en) 2013-09-09 2015-03-12 Calixa Therapeutics, Inc. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
CN104523430A (zh) * 2014-12-17 2015-04-22 吉林敖东世航药业股份有限公司 中药材的冰冻低温超微粉碎方法
CN104784125B (zh) * 2015-04-14 2017-10-03 海南皇隆制药股份有限公司 一种注射用萘普生钠冻干粉针制剂及其制备方法
KR20190039137A (ko) 2016-07-14 2019-04-10 아카오젠, 인코포레이티드 박테리아 감염 치료에서 사용하기 위한 세프티부텐과 클라불란산의 조합
CN109364777B (zh) * 2018-10-25 2021-08-06 瑞阳制药股份有限公司 美洛西林钠和舒巴坦钠混粉的制备方法及装置
DE102019219184A1 (de) 2019-12-09 2021-06-10 Robert Bosch Gmbh Elektrischer Leiter aus Graphen und/oder Kohlenstoffnanoröhren mit beschichteten Fügestellen
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport
AU2022253899A1 (en) 2021-04-07 2023-10-26 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
DE29502547U1 (de) * 1995-02-16 1995-03-30 Röhm GmbH, 64293 Darmstadt Thermoplastisches Überzugs- und Bindemittel für Arzneiformen
US5529800A (en) * 1995-02-17 1996-06-25 General Mills, Inc. Low density ready-to-spread frosting and method of preparation
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
CA2227314A1 (en) 1997-01-24 1998-07-24 Hoechst Aktiengesellschaft Preparation of concealed taste preparations of antibacterially active quinolone derivatives
WO1999017742A2 (en) 1997-10-03 1999-04-15 Elan Corporation, Plc Taste masked formulations
FR2781152B1 (fr) 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
DE19918435A1 (de) * 1998-07-23 2000-01-27 Roehm Gmbh Überzugs- und Bindemittel für orale oder dermale Arzneiformen
DE19958007A1 (de) 1999-12-02 2001-06-07 Roehm Gmbh Spritzgußverfahren für (Meth)acrylat-Copolymere mit teritiären Ammoniumgruppen
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
US7160558B2 (en) * 2001-02-27 2007-01-09 Roehm Gmbh & Co. Kg Coating and binding agent for pharmaceutical formulations with improved storage stability
BR0211117A (pt) 2001-07-16 2004-06-22 Astrazeneca Ab Tablete multiparticulado, processo para a manufatura e uso do mesmo, e, método e tratamento de distúrbios gastrointestinais
DE10208344A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Schmelzextrusion von Wirkstoffsalzen
DE10239999A1 (de) * 2002-08-27 2004-03-04 Röhm GmbH & Co. KG Granulat oder Pulver zur Herstellung von Überzugs- und Bindemitteln für Arzneiformen
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung

Also Published As

Publication number Publication date
MXPA05007643A (es) 2005-09-30
JP2014159424A (ja) 2014-09-04
US20130071475A1 (en) 2013-03-21
KR100983461B1 (ko) 2010-09-27
IL169886A0 (en) 2007-07-04
JP5537756B2 (ja) 2014-07-02
EP1587497B1 (de) 2014-11-12
WO2004066976A1 (de) 2004-08-12
SI1587497T1 (sl) 2015-03-31
US20060051412A1 (en) 2006-03-09
CA2512738A1 (en) 2004-08-12
ES2528359T3 (es) 2015-02-09
PL206413B1 (pl) 2010-08-31
KR20050096952A (ko) 2005-10-06
AU2003292061A1 (en) 2004-08-23
US8999385B2 (en) 2015-04-07
EP1587497A1 (de) 2005-10-26
DE10304403A1 (de) 2004-08-05
PL376483A1 (en) 2005-12-27
JP2006514660A (ja) 2006-05-11
CA2512738C (en) 2013-08-13
US8343542B2 (en) 2013-01-01
IL169886A (en) 2010-11-30
BRPI0318049B1 (pt) 2018-04-03
BR0318049A (pt) 2005-12-20

Similar Documents

Publication Publication Date Title
BRPI0318049B8 (pt) processo para produção de uma forma farmacêutica oral com imediata desintegração e liberação de ingrediente ativo, pó contendo ingrediente ativo e seu uso
BR0110321A (pt) Revestimento e agente de ligação para formulações farmacêuticas tendo estabilidade em armazenamento aperfeiçoada
FI971880A0 (fi) Helposti sulavan kantajan sisältävä farmaseuttinen koostumus ja menetelmä sen valmistamiseksi
KR101500769B1 (ko) 위액 내성인 활성 물질 매트릭스를 포함하는 펠렛
DE69838300T2 (de) Pharmazeutische suspensionstabletten-zusammenstellungen
KR100663663B1 (ko) 경구 또는 피부용 제형을 위한 공중합체
BR0306143A (pt) Grânulos ou pó para a produção de agentes de revestimento e aglutinantes para formas farmacêuticas
US20070292508A1 (en) Orally disintegrating dosage forms
US3632778A (en) Tablets containing l-dopa
JPS60209518A (ja) 貯蔵安定性を有し急速に崩壊する薬学的に活性な物質を含有する圧縮成形体及びその製造方法
PT1131050E (pt) Formulacoes galenicas que se desintegram rapidamente na boca e metodo para as preparar
DE4220782A1 (de) Verfahren zur Herstellung von festen pharmazeutischen Retardformen
JPH11322586A (ja) 固体の医薬品および化粧品の製造のためのマトリックスとしての共重合体の使用およびこのマトリックスを含有する医薬品および化粧品
JP2006507216A (ja) 用量ダンピングの恐れを低減させた新規な薬物送達システムとしての徐放性固形製剤
US5959019A (en) Topical tale containing compositions
MD2722B2 (ro) Compoziţie farmaceutică cu carbonat de calciu sau amestecul lui cu hidroxicarbonat de magneziu sau cu vitamina D, utilizată pentru profilaxia sau tratamentul osteoporozei
US3594467A (en) Long-lasting troche
DE1292303T1 (de) Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält
JPS59227817A (ja) 持続性経口用ブレデニン製剤
DE60305642T2 (de) In der mundhöhle dispergierbare pharmazeutische zusammensetzung mit piribedil
ES2117049T3 (es) Procedimiento para la preparacion de una composicion terapeutica util frente a las carencias de magnesio y destinada a garantizar la liberacion del magnesio que contiene.
BR0318167A (pt) formulação de liberação controlada contendo um material hidrofóbico como o agente de liberação controlada
JP2001253818A (ja) 口腔内速崩壊性錠剤
RU2010125505A (ru) Фармацевтический набор из эмульсии типа &#34;масло в воде&#34; и твердой композиции
WO2002019991A1 (de) Multipartikuläre arzneiform und verfahren zu ihrer herstellung

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: ROEHM GMBH AND CO. KG. (DE)

Free format text: AFIM DE ATENDER A ALTERACAO DE NOME, REQUERIDA ATRAVES DA PETICAO NO 020100037359/RJ DE 29/04/2010, ESCLARECA DIVERGENCIA ENTRE O NOME DO TITULAR DO PEDIDO E O NOME QUE DEVE SER ALTERADO.

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: ROEHM GMBH AND CO. KG. (DE)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 020110115266/RJ DE 09/11/2011, E NECESSARIO APRESENTAR GUIA RELATIVA A SEGUNDA ALTERACAO DE NOME OCORRIDA.

B25D Requested change of name of applicant approved

Owner name: ROEHM GMBH (DE)

B25D Requested change of name of applicant approved

Owner name: EVONIK ROEHM GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 11, 13 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/11/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved
B25A Requested transfer of rights approved
B25D Requested change of name of applicant approved